Skip to content
Clinical Trials – home
Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 60

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Hepatic fibrosis+1

Not recruiting

Study comparing how the body processes GB1211 capsule and tablet forms with and without food in healthy volunteers

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:2-(5-BROMOPYRIDIN-3-YL)SULFANYL-6-(HYDROXYMETHYL)-4-[4-(3,4,5-TRIFLUOROPHENYL)TRIAZOL-1-YL]OXANE-3,5-DIOL
  • Sponsor:Galecto Biotech AB

Influenza

Not recruiting

Study of mRNA-based seasonal influenza vaccine to evaluate immune response and safety in adults 18 years and older

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:GSKVX000000034794
  • Sponsor:GlaxoSmithKline Biologicals

Avian influenza

Not recruiting

Study of H5N8 influenza vaccine in adults previously vaccinated with H5N1/MF59 vaccine compared to those never vaccinated with H5 vaccine

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:University Of Antwerp

Study of zoldonrasib in patients with RAS G12D mutation non-small cell lung cancer who have received previous treatment

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
  • Sponsor:Revolution Medicines Inc.

Study of radiotherapy with durvalumab and ceralasertib in patients with stage III non-small cell lung cancer who have thoracic relapse after PACIFIC treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Pertussis

Not recruiting

Study of acellular pertussis vaccine and its effect on whooping cough colonization in healthy adults using controlled human infection

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:Azithromycin
  • Sponsor:Stichting Radboud University Medical Center

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Study of Tozorakimab to reduce exacerbations in former smokers with chronic obstructive pulmonary disease (COPD)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:AstraZeneca AB

Pneumonia viral

Not recruiting

Study of inhaled interferon beta-1a (SNG001) for treatment of patients with viral lower respiratory tract infections who require mechanical ventilation

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Interferon Beta-1A
  • Sponsor:Synairgen Research Limited

Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Amgen Inc.

Study comparing valemetostat tosylate plus pembrolizumab versus pembrolizumab alone in patients with advanced non-small cell lung cancer with high PD-L1 expression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.